Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction

Next Previous
X
Search
Trial Profile

A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
  • Indications COVID 2019 infections; COVID-19 respiratory infection
  • Focus Adverse reactions

    • Most Recent Events

    • 02 Aug 2023 According to an Enlivex Therapeutics media release, data from this study were peer-reviewed published in Frontiers in Immunology.
    • 02 Aug 2023 Results presented in an Enlivex Therapeutics media release.
    • 03 Feb 2021 according to an Enlivex Therapeutics media release, submission of the data summary to regulators is expected later this month and will serve as the basis for a discussion with regulators on the next steps in Allocetras regulatory pathway in COVID-19 patients with severe or critical illness.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top